Dr.SportsMedIN said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 77 96 >60…
Same pattern here, and in the same order. The detail I would add is minor and it is already implied above.
A narrower follow-up, since the general answer is now clear:
What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?
PharmacoVig_BOS said:GFR trending upward on renal function — encouraging for those with mild CKD concerns: Baseline eGFR: 68 → Month 6: 84 → Month 12: 90 The FLOW trial…
The FLOW trial results on renal function and renal outcomes: semaglutide 1.0mg reduced the composite kidney outcome by 24% (HR 0.76, p=0.0003) in CKD patients with T2DM[1].
The trial was stopped early for efficacy — always a strong signal. GFR decline was 1.16 mL/min/1.73m²/year slower with semaglutide. This positions GLP-1 agonists alongside SGLT2 inhibitors as pillars of cardiorenal protection in T2DM.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsPharmacoVig_BOS said:GFR trending upward on renal function — encouraging for those with mild CKD concerns: Baseline eGFR: 68 → Month 6: 84 → Month 12: 90 The FLOW trial…
Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.